PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.82%
R&D growth above 1.5x AXSM's 3.53%. Michael Burry would check for spending discipline.
-13.19%
G&A reduction while AXSM shows 52.03% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
-1.40%
Other expenses reduction while AXSM shows 0.00% growth. Joel Greenblatt would examine efficiency.
-2.45%
Operating expenses reduction while AXSM shows 14.83% growth. Joel Greenblatt would examine advantage.
-2.45%
Total costs reduction while AXSM shows 14.83% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
-1.40%
Both companies reducing D&A. Martin Whitman would check industry patterns.
-13.13%
EBITDA decline while AXSM shows 0.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
2.45%
Operating income growth while AXSM declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
49.45%
Other expenses growth while AXSM reduces costs. John Neff would investigate differences.
10.71%
Pre-tax income growth while AXSM declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.71%
Net income growth while AXSM declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
23.59%
EPS growth while AXSM declines. John Neff would investigate advantages.
23.59%
Diluted EPS growth while AXSM declines. John Neff would investigate advantages.
16.70%
Share count change of 16.70% while AXSM is stable. Bruce Berkowitz would verify approach.
16.70%
Diluted share change of 16.70% while AXSM is stable. Bruce Berkowitz would verify approach.